MMSI Merit Medical Systems Inc.

Merit Medical Launches SafeGuard Focus Cool™ Compression Device

Merit Medical Launches SafeGuard Focus Cool™ Compression Device

Modern design advances patient care by combining hemostasis with innovative cooling capability

SOUTH JORDAN, Utah, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the launch of its SafeGuard Focus Cool™ Compression Device, an innovative addition to its SafeGuard® platform. It is part of a broader cardiac portfolio that offers products and accessories necessary for cardiac rhythm management, electrophysiology, and lead extraction procedures as well as interventional cardiac resynchronization therapy.

The new compression device builds upon the original SafeGuard Focus™, a revolutionary idea that provides compression over closed surgical sites which can assist hemostasis in patients with pacemaker and implantable cardioverter defibrillator (ICD) pockets. The SafeGuard Focus Cool offers the same high performance but with an easy-to-prepare cooling solution that does not require refrigeration, making it ideal for the lab environment.

More than 1 million cardiac pacemakers are implanted every year worldwide, with 200,000 implanted in the United States alone.1 In addition, more than 200,000 ICDs are implanted each year globally.2 As the older population continues to grow and these devices receive expanding applications, the patient need for these therapies is also expected to increase.1,2

“Access site complications, including swelling, discomfort, bleeding, and infections, are things that concern physicians after pacemaker and ICD implants. They may impact the patient experience, create clinical risk, and prolong hospitalization. Physicians are looking for solutions to improve post-implant care,” said Dr. Grant Simons, Chief of Heart Rhythm Services at Englewood Health NJ. “In my practice, I’ve already seen the advantages of SafeGuard Focus in providing controlled compression with a simple, convenient device. We see adding a cooling feature to the device as an advantage for our patients." Dr. Grant Simons and his team were the first globally to use the SafeGuard Focus Cool compression device on patients. Procedures were performed with excellent outcomes despite uninterrupted anticoagulation.

.

“Our ongoing collaboration with physicians allows us to understand their specific clinical needs,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “The SafeGuard Focus Cool is the result of Merit’s fundamental drive to react quickly to these needs, innovating and delivering solutions that advance patient care.”

ABOUT MERIT MEDICAL 

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS 

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions. 

CONTACTS

PR/Media Inquiries

Sarah Comstock 

Merit Medical

|  

INVESTOR INQUIRIES

Mike Piccinino, CFA, IRC  

Westwicke - ICR  

|

REFERENCES 

  1. Bhatia N & El-Chami M. 2018. “Leadless Pacemakers: A Contemporary Review.” J Geriatr Cardiol 15, no. 4 (Apr): 249 ̶ 253. PMID 29915613.
  2. Ammannaya G. 2020. “Implantable Cardioverter Defibrillators—the Past, Present and Future.” Arch Med Sci Atheroscler Dis. 5: e163 ̶ e170. PMID: 32832716.


EN
08/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Provides Update on U.S. Reimbursement and Commercial Str...

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further conside...

 PRESS RELEASE

Merit Medical Releases 24-Month Efficacy Results from the Randomized A...

Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ILMN ILLUMINA INC.
YNDX YANDEX NV CLASS A
WDC WESTERN DIGITAL CORPORATION
TTMI TTM TECHNOLOGIES INC.
RUN SUNRUN INC.
OSIS OSI SYSTEMS INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NWPX NORTHWEST PIPE CO.
MMSI MERIT MEDICAL SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LOCO EL POLLO LOCO HOLDINGS INC
KWR QUAKER CHEMICAL CORPORATION
HNRG HALLADOR ENERGY CO.
GALT GALECTIN THERAPEUTICS
EXPO EXPONENT INC.
BRKR BRUKER CORPORATION
AXTI AXT INC.
ASPN ASPEN AEROGELS
GASS STEALTHGAS
BJRI BJ'S RESTAURANTS INC.
AUP AURINIA PHARMACEUTICALS INC.
NVT NINH VAN BAY REAL ESTATE
ATEC ALPHATEC HOLDINGS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
FSLR FIRST SOLAR INC.
LPLA LPL FINANCIAL HOLDINGS INC.
TWLO TWILIO INC. CLASS A
HCC WARRIOR MET COAL INC.
BTU PEABODY ENERGY CORPORATION
NEXA NEXA RESOURCES S.A.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
OPXSD OPTEX SYSTEMS HOLDINGS INC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
TVTX TRAVERE THERAPEUTICS INC
AMR ALPHA METALLURGICAL RESOURCES INC
CGEM CULLINAN ONCOLOGY INC
MMED MIND MEDICINE MINDMED
MRVL MARVELL TECHNOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
NVTS NAVITAS SEMICONDUCTOR CORP
APG API GROUP CORP
JOBY JOBY AVIATION INC
SPXC SPX TECHNOLOGIES INC
IE IVANHOE ELECTRIC INC
AMPX AMPRIUS TECHNOLOGIES INC
DUOT DUOS TECHNOLOGIES GROUP INC
IMPP IMPERIAL PETE INC
LAES SEALSQ CORP
LXEO LEXEO THERAPEUTICS INC
METC RAMACO RESOURCES INC.
RAPP RAPPORT THERAPEUTICS INC
TOYO TOYO CO LTD
CLNN CLENE INC
FCEL FUELCELL ENERGY INC.
QUIK QUICKLOGIC CORP
GSAT GLOBALSTAR INC.
ACA ALDA CAPITAL CORP COM
 PRESS RELEASE

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm A...

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breakin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch